Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia

Portmann-Baracco A.S.; Alcorta-Proaño R.G.; Nuñez-Mochizaki C.; Webb C.M.; Trelles J.; Caparo C.; La Rosa M.F. · American Journal of Perinatology (2023) · DOI: 10.1055/a-2099-8758

Resumen

Objective Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery. Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G +, IgM +, or both IgG+ and IgM +. Bivariate and multivariable analyses were performed. Results We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98-36.09; p < 0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65-18.02; p < 0.05). Conclusion We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.

Instituciones: Universidad Peruana Cayetano Heredia